Sign in
IMCR Stock Price, Chart, Stats & News
Immunocore Holdings plc
Save
1.52B
Market cap
–
Current P/E
196.08x
Forward P/E
IMCR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 98.66% |
Operating margin | -10.79% |
Pretax margin | -4.02% |
Net margin | -7.18% |
Effective tax rate | -78.33% |
ROA | -2.51% |
ROE | -6.93% |
D/E | 0.11x |
Interest coverage ratio | -3.30x |
IMCR valuation
P/E | – |
P/S | 4.00x |
P/B | 3.89x |
P/CF | -138.37x |
P/FCF | -99.14x |
P/OCF | -138.37x |
PEG | -10.34x |
EV multiple | -5902.69x |
About
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized.
Similar securities
Based on sector and market capitalization
Report issue